This supplementary appendix provides additional information to support the study by Mehra MR, Desai SS, Kuy S, Henry TD, and Patel AN, published in the New England Journal of Medicine. It includes supplementary figures and tables that delve deeper into the analysis of cardiovascular disease, drug therapy, and mortality in COVID-19 patients. **Supplementary Figures:** - Figure S1: Association Between Age and Mortality **Supplementary Tables:** - **Table S1:** Study sample by continent, country, and number of hospitals. - **Table S2:** Summary data by continent. - **Table S3:** Summary data for High Income Countries (HIC) and Low-Middle Income (LMIC) Countries, defined based on WHO classifications. - **Table S4:** Multivariable logistic regression analysis by continent for in-hospital mortality. - **Table S5:** Multivariable logistic regression analysis for in-hospital mortality in Low-Middle Income Countries. - **Table S6:** Age- and sex-adjusted multivariable logistic regression analysis for in-hospital mortality. - **Table S7:** Tipping point analysis for unmeasured confounders, assessing the effects of an unmeasured confounder on the significance of ACE inhibitors or statins. - **Table S8:** Subgroup analyses for hypertension and hyperlipidemia, evaluating the association between ACE inhibitors and statins and mortality in these subgroups. The appendix also includes a tipping point analysis to assess the impact of an unmeasured confounder on the significance of ACE inhibitors and statins, and subgroup analyses to confirm the findings in patients with hypertension and hyperlipidemia. The 95% confidence intervals in all analyses have not been adjusted for multiple testing and should not be used to infer definitive effects.This supplementary appendix provides additional information to support the study by Mehra MR, Desai SS, Kuy S, Henry TD, and Patel AN, published in the New England Journal of Medicine. It includes supplementary figures and tables that delve deeper into the analysis of cardiovascular disease, drug therapy, and mortality in COVID-19 patients. **Supplementary Figures:** - Figure S1: Association Between Age and Mortality **Supplementary Tables:** - **Table S1:** Study sample by continent, country, and number of hospitals. - **Table S2:** Summary data by continent. - **Table S3:** Summary data for High Income Countries (HIC) and Low-Middle Income (LMIC) Countries, defined based on WHO classifications. - **Table S4:** Multivariable logistic regression analysis by continent for in-hospital mortality. - **Table S5:** Multivariable logistic regression analysis for in-hospital mortality in Low-Middle Income Countries. - **Table S6:** Age- and sex-adjusted multivariable logistic regression analysis for in-hospital mortality. - **Table S7:** Tipping point analysis for unmeasured confounders, assessing the effects of an unmeasured confounder on the significance of ACE inhibitors or statins. - **Table S8:** Subgroup analyses for hypertension and hyperlipidemia, evaluating the association between ACE inhibitors and statins and mortality in these subgroups. The appendix also includes a tipping point analysis to assess the impact of an unmeasured confounder on the significance of ACE inhibitors and statins, and subgroup analyses to confirm the findings in patients with hypertension and hyperlipidemia. The 95% confidence intervals in all analyses have not been adjusted for multiple testing and should not be used to infer definitive effects.